Literature DB >> 9232455

Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity.

B Wittig1, S Seiter, N Föger, C Schwärzler, U Günthert, M Zöller.   

Abstract

There is ample evidence that the family of CD44 glycoproteins is involved in homing, maturation and activation of lymphocytes. Furthermore, recent evidence suggests that CD44 splice variants are particularly involved in the process of lymphocyte activation whereby it was hypothesized that different isoforms may fulfill distinct functions. We here addressed the question of CD44v6 and CD44v7 being involved in TH1 and TH2 reactions using as model systems for TH1 activation a TNBS-induced colitis and a DNFB-induced DTH reaction and for TH2 activation a FITC-induced allergic dermatitis. With the exception of a small subpopulation of lymphocytes in Peyer's patches, expression of neither CD44v6 nor CD44v7 was noted in the absence of an antigenic stimulus. Both CD44 variant exons are transiently detected on T lymphocytes during mounting of an immune response. In vitro studies revealed that antibodies against both CD44v6 and CD44v7 inhibited lymphocyte proliferation and cytokine production. Based on these findings the efficiency of anti-CD44v6 and anti-CD44v7 treatment was evaluated in vivo in TH1 and TH2 dependent autoimmune and DTH reactions. Anti-CD44v7 completely abrogated development of a death promoting colitis and anti-CD44v6 as well as anti-CD44v7 significantly mitigated the DNFB-induced, TH1-mediated DTH reactions, while only anti-CD44v7 interfered with a FITC-induced, TH2-mediated allergic contact dermatitis. The in vitro analysis of cytokine producing cells supported the assumption. In conclusion, it could be demonstrated that CD44v6 and CD44v7 are differentially involved in TH1 and TH2 activation and, most importantly, a TH1-mediated autoimmune disease could be prevented by local application of anti-CD44v7.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9232455     DOI: 10.1016/s0165-2478(97)00060-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  Intermediate Molecular Mass Hyaluronan and CD44 Receptor Interactions Enhance Neutrophil Phagocytosis and IL-8 Production via p38- and ERK1/2-MAPK Signalling Pathways.

Authors:  Cheng-Hsun Lu; Chia-Huei Lin; Ko-Jen Li; Chieh-Yu Shen; Cheng-Han Wu; Yu-Min Kuo; Ting-Syuan Lin; Chia-Li Yu; Song-Chou Hsieh
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

2.  Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice.

Authors:  S Farkas; M Hornung; C Sattler; M Anthuber; U Gunthert; H Herfarth; H J Schlitt; E K Geissler; B M Wittig
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

3.  Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance.

Authors:  M Athanassiou-Papaefthymiou; O Shkeir; D Kim; V Divi; M Matossian; J H Owen; M J Czerwinski; P Papagerakis; J McHugh; C R Bradford; T E Carey; G T Wolf; M E Prince; S Papagerakis
Journal:  Int J Immunopathol Pharmacol       Date:  2014 Jul-Sep       Impact factor: 3.219

4.  The role of CD44 in cutaneous inflammation.

Authors:  Mona Man; Peter M Elias; Wenyan Man; Yan Wu; Lilly Y W Bourguignon; Kenneth R Feingold; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2009-03-26       Impact factor: 3.960

5.  Comprehensive Screening of Gene Function and Networks by DNA Microarray Analysis in Japanese Patients with Idiopathic Portal Hypertension.

Authors:  Kohei Kotani; Joji Kawabe; Hiroyasu Morikawa; Tomohiko Akahoshi; Makoto Hashizume; Susumu Shiomi
Journal:  Mediators Inflamm       Date:  2015-10-04       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.